Womastin Injection, containing Carboplatin 150mg, is a platinum-based chemotherapeutic agent indicated for the treatment of various malignancies, including ovarian, lung, head and neck, and testicular cancers. Carboplatin exerts its antineoplastic effects by forming DNA crosslinks, thereby inhibiting DNA synthesis and inducing apoptosis in rapidly dividing cancer cells. Administered intravenously, Womastin Injection requires careful dosing based on renal function and body surface area to minimize toxicity. Common adverse effects include myelosuppression, particularly thrombocytopenia and neutropenia, as well as nausea, vomiting, and nephrotoxicity. Hypersensitivity reactions, although less frequent than with cisplatin, may occur and necessitate immediate medical attention. Regular monitoring of blood counts, renal function, and electrolytes is essential during therapy. Womastin Injection should be used under strict oncological supervision, with appropriate supportive care to manage side effects. It is contraindicated in patients with hypersensitivity to carboplatin or other platinum compounds and should be used cautiously in those with pre-existing renal impairment or bone marrow suppression. Pregnancy and lactation are contraindications due to potential teratogenic effects. Womastin Injection represents a critical component in combination chemotherapy regimens aimed at improving survival outcomes in patients with solid tumors.